Investing.com -- Evommune Inc. (NYSE:EVMN) stock soared 64% after the clinical-stage biotechnology company announced positive top-line results from its Phase 2a trial evaluating EVO301 in patients ...

According to MarketsandMarkets™, the IV Equipment Market is projected to grow from about USD 17.82 billion in 2026 to USD ...

Aptamer-coated microneedle patch can detect amounts of the antibiotic vancomycin in real time for at least 12 hours ...

Use this calculator to find out how much fiber you need. Plus, learn about the top sources of fiber, how to increase fiber ...

Investing.com -- Aquestive Therapeutics (NASDAQ:AQST) stock rose 18% Monday despite the company announcing it received a complete response letter (CRL) from the U.S. Food and Drug Administration for ...

Drs Robert Glatter and Ken Milne discuss what the recent RSI trial reveals — and does not reveal — about choosing etomidate ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced ...

Good day, everyone. My name is Megan, and I will be your conference operator today. At this time, I would like to welcome you to Xencor XmAb819 Initial Phase I Dose Escalation Results Webcast.

Department of Radiation Oncology, General Hospital of Northern Theater Command, Shenyang, China Background: Accurate dose calculation algorithms are critical for optimizing radiotherapy outcomes. This ...

Objective Intraosseous access is recommended as a reasonable alternative for vascular access during newborn resuscitation if umbilical access is unavailable, but there are minimal reported data in ...

Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) intravenous (IV) infusion in adult patients with relapsing multiple ...